Eli Lilly and Company (LLY) Fundamentals

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
SHARE INFORMATION
Market Cap$ 300,939,368,040
Shares Outstanding950,174,817
Float789,650,774
Percent Float83.11%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 3.40
Latest Fiscal Revenue$ 28,318,400,000
Latest Fiscal EPS$ 6.13
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 12.71
Dividend (5 Years)$ 11.34
Ex Dividend Date2022-08-12
Dividend Rate$ 3.92
Dividend Yield1.24%
Payment CashCash
HOLDERS
Institutions3,778
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months49,967,485
Institutional Holdings Percent142.8%
Institutional Sold Previous 3 Months48,663,893
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months8,180
Insider Holdings Percent0.5
Insider Sold Previous 3 Months1,710,095
Insider Shares Owned4,725,766
TRADING INFO
52 Week High$ 335.33
52 Week Low$ 220.20
52 Week High Change$ 19.62
21 Day Moving Average$ 315.9107
21 Day Extended Moving Average$ 314.2983
50 Day Moving Average$ 315.0539
50 Day Extended Moving Average$ 313.4052
200 Day Moving Average$ 280.1995
200 Day Extended Moving Average$ 285.1729
10 Day Average Volume2,506,003
20 Day Average Volume2,678,149
30 Day Average Volume2,495,075
50 Day Average Volume2,702,823
Alpha0.024292
Beta0.3479
Standard Deviation0.074467
R20.054588
7 Day Price Change$ 16.53
7 Day Percent Change5.51%
21 Day Price Change$ -13.00
21 Day Percent Change-3.94%
30 Day Price Change$ -4.00
30 Day Percent Change-1.25%
Month to Date Price Change$ -11.90
Month to Date Percent Change-3.62%
Quarter to Date Price Change$ -6.45
Quarter to Date Percent Change-2.0%
180 Day Price Change$ 78.00
180 Day Percent Change32.67%
200 Day Price Change$ 74.25
200 Day Percent Change30.62%
Year to Date Price Change$ 43.46
Year to Date Percent Change15.91%

Eli Lilly and Company (LLY) Key Ratios

PROFITABILITY
EBIT Margin22.6%
EBITDA Margin28.1%
Pre-Tax Profit Margin21.0%
Profit Margin Count19.53%
Gross Margin76.0%
Profit Margin TOT19.53%
INCOME STATEMENTS
Revenue$ 29,070,700,000
Revenue Per Share$ 30.5951
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book-105.80
Total Debt To Equity2.00
Int Coverage19.80
Current Ratio1.10
Leverage Ratio5.50
Quick Ratio0.70
Long Term Debt To Capital0.63
VALUATION MEASURES
PE Ratio50.60
Enterprise Value$ 315,111,485,521
Price to Sales10.352
Price to Free Cash183.90
PE High Last 5 Years43.80
Price To Book35.20
Price To Cash Flow40.50
PE Low Last 5 Years-409.40
Price to Tangible Book-105.80
MANAGEMENT EFFECTIVENESS
Receivables Turnover4.10
Invoice Turnover1.90
Assets Turnover0.60
Return Assets12.75
Return on Equity79.94
Return on Capital24.69

Eli Lilly and Company (LLY) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEODavid A. Ricks
Emplyoees35000
Last AuditUQ
CIK0000059478
IndustryDrug Manufacturers
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
AddressLilly Corporate Center
Indianapolis, IN 46285
Websitehttps://www.lilly.com
Facsimile-
Telephone+1 317 276-2000
Emailhern_kevin_r@lilly.com


Your Recent History
NYSE
LLY
Eli Lilly
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.